**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript No: 6599**

**Columns: TOPIC HIGHLIGHTS**

WJG 20th Anniversary Special Issues (14): Pancreatic cancer

**MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer**

Gayral M *et al*. microRNAs in pancreatic cancer

Marion Gayral, Sébastien Jo, Naima Hanoun, Alix Vignolle-Vidoni, Hubert Lulka, Yannick Delpu, Aline Meulle, Marlène Dufresne, Marine Humeau, Maël Chalret du Rieu, Barbara Bournet, Janick Sèlves, Rosine Guimbaud, Nicolas Carrère, Louis Buscail, Jérôme Torrisani, Pierre Cordelier

**Marion Gayral, Sébastien Jo, Naima Hanoun, Alix Vignolle-Vidoni, Hubert Lulka, Yannick Delpu, Aline Meulle, Marlène Dufresne, Marine Humeau, Maël Chalret du Rieu, Barbara Bournet, Janick Sèlves, Rosine Guimbaud, Nicolas Carrère, Louis Buscail, Jérôme Torrisani, Pierre Cordelier,** Cancer Research Center of Toulouse Team 10, UMR INSERM U1037, Université Paul Sabatier, 31432 Toulouse, France

**Alix Vignolle-Vidoni, Marine Humeau, Maël Chalret du Rieu, Barbara Bournet, Janick Sèlves, Rosine Guimbaud, Nicolas Carrère, Louis Buscail,** Pôle Digestif, Centre Hospitalier Universitaire Toulouse, 31432 Toulouse, France

**Author contributions:** Gayral M, Jo S, Hanoun N, Vignolle-Vidoni A, Lulka H, Delpu Y, Meulle A, Dufresne M, Humeau M, Chalret du Rieu M, Bournet B, Sèlves J, Guimbaud R, Carrère N, Buscail L, Torrisani J and Cordelier P contributed to the bibliographical review; Gayral M, Torrisani J and Cordelier P wrote the paper.

**Correspondence to: Pierre Cordelier,** **PhD**, Cancer Research Center of Toulouse Team 10, UMR INSERM U1037, Université Paul Sabatier, 118 Route de Narbonne, 31432 Toulouse, France. pierre.cordelier@inserm.fr

**Telephone:** +33-5-61322404  **Fax:** +33-5-61322403

**Received:** October 24, 2013 **Revised:** March 6, 2014

**Accepted:** June 13, 2014

**Published online:**

**Abstract**

Despite tremendous efforts from scientists and clinicians worldwide, pancreatic adenocarcinoma (PDAC) remains a deadly disease due to the lack of early diagnostic tools and reliable therapeutic approaches. Consequently, a majority of patients (80%) display an advanced disease that results in a low resection rate leading to an overall median survival of less than 6 months. Accordingly, robust markers for the early diagnosis and prognosis of pancreatic cancer, or markers indicative of survival and/or metastatic disease are desperately needed to help alleviate the dismal prognosis of this cancer. In addition, the discovery of new therapeutic targets is mandatory to design effective treatments. In this review, we will highlight the translational studies demonstrating that microRNAs may soon translate into clinical applications as long-awaited screening tools and therapeutic targets for PDAC.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Micrornas; Biomarkers; Pancreatic cancer; Therapeutic targets; Precancerous lesions

**Core tip:** Robust biomarkers and reliable treatments are needed to help alleviate the dismal prognosis of pancreatic cancer. In this review, we will highlight the translational studies demonstrating that microRNAs may soon translate into clinical applications as long-awaited screening tools and therapeutic targets for this cancer.

Gayral M, Jo S, Hanoun N, Vignolle-Vidoni A, Lulka H, Delpu Y, Meulle A, Dufresnes M, Humeau M, du Rieu MC, Bournet B, Sèlves J, Guimbaud R, Carrère N, Buscail L, Torrisani J, Cordelier P.MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World J Gastroenterol 2014; In press

**Pancreatic cancer**

There are currently no means for the reliable diagnosis of early stages of pancreatic cancer (PDAC) and the curative treatment of late stages. Consequently, the vast majority of patients (80%) display an advanced disease that results in a low resection rate leading to a dismal overall median survival of less than 6 mo[1]. The estimated 5-year survival rate is lower than 2%. While PDAC is not among the most common tumors, it is one of the most frequent causes of cancer-related death with approximately 40000 death/year in the United States and in Europe. Thus, there is an urgent need to discover diagnostic as well as prognostic molecular markers together with reliable therapeutics to improve pancreatic cancer management.

 PDAC is a highly heterogeneous disease[2] defined by numerous alterations in multiple signaling pathways[3]. Additionally, specific cellular clones for primary tumors and metastasis have been identified[4]. Interestingly, the type and number of genomic rearrangements in DNA vary considerably between patients, and occur early during tumor development[5]. On the other end, pioneering studies using genome-wide profiling showed that microRNAs (miRNA) expression can discriminate cancers with high efficacy[6]. In this review, we will focus on the use of miRNAs as promising biomarkers and therapeutic targets for pancreatic cancer (summarized in Tables 1 to 3).

**General concept of miRNAs and cancer**

miRNAs are small RNA molecules that functions as translation inhibitors of messenger RNA by their binding to 3’-untranslated region[7–9]. These molecules are tightly involved in the regulation of many physiological processes such as development, proliferation, invasion, and apoptosis among others. Interestingly, their expression is profoundly altered in cancer and/or is strongly modulated during carcinogenesis. Thus, the activation of tumor-suppressive miRNAs and the inhibition of oncogenic miRNAs by small molecules or gene transfer may have the potential to provide a fundamentally new approach for the development of cancer therapeutics. Probably the most important advantage in comparison with current approaches targeting single genes is the ability to modulate many different pathways “at once” taking into account that one miRNA can regulate hundreds of genes, frequently in the context of a cell-specific network.

**MiRNAs as diagnostic markers for pancreatic cancer**

To date, many strategies based on high-throughput screening (HTS) are used to discover relevant clinical biomarkers. For PDAC in particular and pancreatic tissue in general, these protocols are often hindered by the intrinsic high levels of many nucleases. Consequently, the high stability of miRNAs in tissues and fluids is a key advantage over protein and mRNA. In addition, miRNAs can be quantified in very low amounts of material and in highly degraded samples, such as small biopsies and fine needle aspirates. This is mandatory to support the use of miRNAs as biomarkers for PDAC at the clinical level. In the next sections, we will update the excellent reviews[2,10–15] and meta-analysis[16] from other groups, and reviews and book chapters we recently published[17–19] on the use of miRNAs as biomarkers in PDAC (summarized in Tables 1 and 2).

Historically, Pr Schmittgen’s group was the first to report the expression profiles of miRNAs in PDAC. They identified miRNAs specifically over expressed in PDAC (miR-376a, miR-301) or in other tumors (miR-155, miR-21, miR-221 and miR-222)[20]. Two additional miRNas (miR-132 and miR-212) were recently reported to be over expressed in PDAC as compared to normal or benign adjacent pancreas to the tumor[21]. Another study by Pr Shao’s group yielded conflicting results as they demonstrated that miR-132 was down regulated in cancer *vs* normal benign normal tissues[22]. Other miRNAs, such as miR-96[23], miR-34a[24] and miR-21[25], have been reported to be altered in PDAC as compared to normal adjacent tissue. MiRNAs expression may also help to discriminate PDAC from chronic pancreatitis. This is of particular importance to prevent from unnecessary and possibly debilitating surgery, or to delay tumor treatment, respectively. Historically, Pr Bloomston’s group reported that 21 miRNAs with increased expression and 4 underexpressed miRNAs differentiated PDAC from normal tissue in 90% of samples and from pancreatitis with 93% accuracy[26]. Twenty additional miRNAs were discovered by Szafranska *et al*[27] to discriminate between PDAC, chronic pancreatic and normal pancreas. Later, expression of miR-203[28], miR-148a[29], miR-196b[29], miR-196a[29] and miR-205[29] were demonstrated to be altered in PDAC *vs* chronic pancreatitis. Alternatively, miRNA expression profiles have been recently used to distinguish PDAC from cholangiocarcinoma, two virtually indistinguishable cancers using conventional histopathological and clinical characteristics[30].

Endoscopic ultrasound-guided fine needle aspirations (FNA) material allows for the screening of the vast majority (> 85%) of PDAC patients that are not eligible for surgery, and, as consequence, may provide new insights for the diagnosis and prognosis of PDAC. Pr Szafranska’s group was the first to demonstrate that the expression of miR-196a and miR-217 in FNA material can classify PDAC from benign lesion[31]. This pioneering study led to the development of the first molecular test for the identification of PDAC[32]. Hence, we demonstrated that *let-7* miRNA expression is repressed in PDAC FNAs[33], and that the measurement of hypermethylation of miR-148a encoding DNA region is potentially useful to differentiate PDAC and pseudo-tumor forms of chronic pancreatitis[34].

**MiRNAs as prognostic and predictive markers for pancreatic cancer**

MiRNAs are also scrutinized for their ability to predict cancer prognosis and/or response to treatment. Bloomston *et al*[26] were the first to report that miR-452, miR-105, miR-127, miR-518a-2, miR-187, and miR-30a-3p are over-expressed in the tumors of patients with survival greater than 2 years. Moreover, tumors with high expression of miR-196a-2 or miR-219 have a lower median survival compared with those with low expression. In addition, over expression of miR-155[35], miR-200[35], miR-203[35], miR-205[35], miR-200c[36], miR-21[37], miR-212[38] and miR-675[38] and reduced expression of miR-34a[37], miR-30d[37], miR-148a[38], miR-187[38], miR-130b[39] and *let-7g*[38] in PDAC are associated with poorer survival rate. Last, low miR-211 expression was demonstrated as an independent factor of poor prognosis in resected PDAC[40].

Gemcitabine is broadly used as a first-line chemotherapeutic treatment for patients with unresectable locally advanced or metastatic pancreatic cancer[41]. However, the 5-year survival rate is only 2%[42], with 1-year survival rates ranging from 17% to 23%[41]. Recently, phase II and III trials exploring gemcitabine-based combinations with erlotinib[43] , FOLFIRINOX[44] or nab-Paclitaxel[45] were found to improve overall survival of patients. However, the moderate activity of standard gemcitabine and gemcitabine-based regimens still encourages the discovery of robust biomarkers that may help to stratify PDAC patients for tailored therapy. Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in PDAC. Recent studies have revealed that high levels of hENT1 in PDAC predict longer survival times in patients treated with adjuvant gemcitabine[46]. In another study, CO-101, a lipid-drug conjugate of gemcitabine, was designed to enter cells independently of hENT1[47]. However, CO-101 was found not superior to gemcitabine in patients with metastatic PDAC and low tumor hENT1. In addition, metastasis hENT1 expression doesn’t predict gemcitabine outcome. Interestingly, Giovannetti *et al*[48] found that high miR-21 expression in tumors is associated with shorter overall survival both in the metastatic and in the adjuvant setting, while patients with low miR-21 expression may benefit from gemcitabine treatment[49]. Gemcitabine resistance is also associated with the cellular over expression of miR-146 and the reduced expression of miR-205 and miR-7[50]. Last but not least, Pr Korc’s group recently demonstrated that miR-10b is a novel and powerful diagnostic biomarker for PDAC[51]. Like miR-21, miR-10b is over expressed in the FNA material from PDAC patients. Additionally, reduced expression of miR-10b is associated with improved response to multimodality neoadjuvant therapy, likelihood of surgical resection, delayed time to metastasis, and increased survival. Thus, miR-10b is likely to be a novel marker to diagnose PDAC, but may also serve as a biomarker for response to gemcitabine-based neoadjuvant therapy, and be predictive of early metastasis formation. In experimental models, miR-10b was demonstrated to promote PDAC-derived cells proliferation and invasion by suppressing TIP30, which enhances EGFR signaling, facilitates EGF-TGF-β cross-talk together with the expression of EMT-promoting genes[52].

**Circulating miRNAs as biomarkers for pancreatic cancer**

The recent discovery of miRNAs in serum or plasma opens up the possibility of using non coding RNAs as circulating biomarkers of disease. Wang J *et al*[53] were the first to report the detection of miRNA in the blood of PDAC patients. They demonstrated that plasmatic miR-21, miR-210, miR-196a and miR-155 reveal a sensitivity of 64% and a specificity of 89% for PDAC. A recent study further confirmed that circulating miR-210[54] and miR-21[55] are elevated in PDAC patients and may potentially serve as a useful biomarker for PDAC diagnosis. In addition, miR-200a[56], miR-200b[56], miR-16[57], miR-196a[57], miR-20a[55], miR-24[55], miR-25[55], miR-99a[55], miR-185[55], miR-221[58] and miR-191[55] were described as significantly elevated in the sera of PDAC as compared with controls. Combining miR-16[57] and miR-196a[57], or miR-27a-3p[59] detection with CA 19-9 quantification is even more effective to discriminate PDAC from controls. However, Pr Hoheisel’s group recently reported that blood miRNAs profile could not discriminate pancreatitis from PDAC efficiently[60]. Last, but not least, Pr Goggin’s group recently demonstrated that miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls[61]. Such study paves the way for the non-invasive detection of early PDAC lesions.

**Open question: what is the significiance of miRNAs in high risk patients for developing pancreatic cancer?**

One of the current avenues of research to improve the management of pancreatic cancer is to better understand the early stages of the disease in order to allow for curative surgery and to prevent the risk of cancer in populations at risk. Advances in biomedical research have led to recent evidence that pancreatic cancer develops from preneoplastic lesions which can be considered as very effective risk factors. Three types of lesions have been identified so far: pancreatic intraepithelial neoplasia (PanIN), mucinous cystadenomas , and Intraductal Papillary Mucinous Neoplasia of the pancreas (IPMN). Interestingly, the latter lesions can be readily detected due to the progress and the multiplicity of the imaging devices in the clinical departments. The risk of degeneration of IPMNs varies according to the type of injured duct: it is of the order of 60% for IPMN located in the main duct (or mixed) while this risk is estimated at 15% for branch ducts. IPMN now represent 25% of the diagnosed pancreatic cystic tumors and 20% of resected pancreatic tumors, respectively. Therefore, one of the most promising strategies to improve the dismal prognosis of pancreatic cancer is to identify early indicators of degeneration of IPMNs in populations at high risk of developing this cancer. Interestingly, MiRNAs have recently revealed a great potential as reliable early diagnosis biomarkers in IPMNs. Again, miR-21 and miR-155 are highly expressed in IPMN, while miR-155 is elevated in IPMN-associated pancreatic juice as compared to controls[62]. We demonstrated that miR-205 and miR-21 overexpression precede phenotypic changes in the pancreatic ducts, both in human samples and in transgenic mice developing cancer[63]. Interestingly, such over expression may occur early in the transformation from normal pancreatic tissue, as benign cystic tumors of low and high malignant potential express high levels of this miRNA[64]. This strongly suggests that miRNAs such as miR-21 can possibly be used for an early diagnosis of this neoplasm. In a similar experimental model, Yabushita *et al*[65] recently reported the over expression of miR-155, miR-21, miR-210, miR-18a, miR-203, miR-30b-5p, miR-31, miR369-5p, miR3-376a and miR-541 in the serum of a human KRAS oncogenic transgenic rat model. More importantly, Matthaei *et al*[66] assessed the diagnostic benefit of using miRNAs as biomarkers in pancreatic cyst fluid in patients, to identify IPMN that require resection and exclude non-mucinous cysts with a sensitivity of 89%, a specificity of 100%, and AUC of 1. This work was further completed by Pr Giovannetti’s group who demonstrated that miR-21, miR-155 and miR-101 showed significant differences in invasive *vs* non-invasive IPMNs, with miR-21 described as an independent prognostic biomarker in invasive IPMNs[67]. Again, miR-21 and miR-155 were recently described as upregulated during the development and progression of IPMN[68]. MiR-21 in cystic fluid was identified as a candidate biomarker to distinguish between benign, premalignant, and malignant cysts[69], while miR-221 could be used for the identification of more advanced malignant disease[69]. Last, a work from Pr Maitra’s group recently revealed that a 9-miRNA panel quantified in cystic fluid may aid in diagnosis and surgical treatment decisions for patients with pancreatic cystic lesions, such as high-grade IPMNs[66]. Thus, miRNAs may reveal as non-invasive indicators of degeneration in a population at high risk of developing incurable cancer. Once identified, patients will be stratified and will benefit from early surgical management that will greatly improve their survival and prognosis. Finally, this approach is likely to strengthen the surveillance protocol and to reduce the costs associated with patients care.

**Role of MiRNAs in pancreatic cancer**

***MiRNAs are broadly involved in pancreatic carcinogenesis***

Many miRNAs have been reported to alter cancer proliferation and/or migration, both *in vitro* and *in vivo*. miR-132 and miR-212 were recently reported to be over expressed in pancreatic cancer as compared to normal or benign adjacent pancreas to the tumor[21]. Interestingly, these miRNAs target the retinoblastoma tumor suppressor 1 (Rb1) to favor cancer cell proliferation[21]. Another study by Pr Shao’s group yielded conflicting results as they demonstrated that miR-132 was down regulated in cancer *vs* normal benign normal tissues[22]. In the later study, enforced expression of miR-132 in cell lines derived from PDAC led to proliferation and colony formation inhibition[22]. Yu *et al*[23] reported that miR-96 is downregulated in PDAC as compared to normal tissues and targets KRAS. Consequently, restoring miR-96 expression strongly inhibited *in vitro* cell proliferation, invasion, induced apoptosis and reduced tumor growth. This was further confirmed in a recent study linking ecotropic viral integration site 1 (EVI1) oncoprotein-mediated inhibition of miR-96 to promote KRAS expression during early pancreatic carcinogenesis[70]. MiR-198 acts as a central tumor suppressor in PDAC and modulates the expression of many oncogenic factors such as MSLN, OCT-2, PBX-1, and VCP[71]. Very interestingly, low miR-198 expression prognosticates poor patient outcome, while high miR-198 may disrupt this oncogenic network and predict better prognosis and increased survival.

***Epigenetic regulation of miRNAs involved in pancreatic cancer progression***

MiR-148 family members may have distinct effects on PDAC-derived cells proliferation. While miR-148a expression is lost during PDAC carcinogenesis following methylation of its DNA sequence[34], we recently demonstrated that enforced expression of this miRNA didn’t impaired PDAC-derived cells cell proliferation nor tumor growth in experimental models[72]. On the other hand, recent results described that miR-148b can inhibit cell proliferation, invasion, and enhance chemosensitivity of PDAC by targeting AMPKα1[73]. MiR-124 is also silenced by aberrant methylation in PDAC; consequently, tumor progression and metastasis are enhanced due to the lack of Rac1 targeting[74]. MiR-34a miRNA, which is directly regulated by p53, is also subjected to epigenetic silencing in numerous neoplasms, including PDAC[75]. Strikingly, this miRNA plays a pivotal role in PDAC stem cell self-renewal and may hold significant promise as novel target for PDAC[24]. In addition, the natural compound genistein up-regulates this miRNA to suppress cell proliferation and induce cell death by apoptosis of PDAC-derived cell lines[76]. MiR-34a was also recently reported as a tumor metastasis suppressor by negatively modulating Smad3[77]. Last, Li *et al*[78] recently demonstrated that the histone methyltransferase Enhancer of zeste homolog 2 (EZH2) inhibits miR-218 expression, that prevents proliferation of PDAC cells in culture, and tumor growth and metastasis in nude mice.

***MiRNAs regulates the epithelial-mesenchymal transition in pancreatic cancer***

Besides the miR-200 family members (reviewed elsewhere), miRNAs such as miR-197 and miR-655 have been recently involved in the epithelial-mesenchymal transition in PDAC cells, by targeting p120 catenin[79] and ZEB1 and TGFBR2, respectively[80]. In addition, MicroRNA-221 participates in the effects of PDGF-BB on migration, proliferation, and to the epithelial-mesenchymal transition in these cells[81].

**MiRNAs are key players in drug-mediated inhibition of pancreatic cancer growth**

Recently, different molecules were found to alter miRNA expression in PDAC to inhibit cell proliferation and/or tumor growth. Triptolide that downregulates HSP70, a molecular chaperone upregulated in several tumor types, was recently shown to upregulate miR-142-3p in PDAC cells, to inhibit cell proliferation[82]. More importantly, Minnelide, a water-soluble prodrug of triptolide, induces the expression of miR-142-3p *in vivo*. In addition, the adamantyl retinoid-related (ARR) molecule 3-Cl-AHPC was recently demonstrated to induce miR-150\* and miR-630 miRNAs expression to target IGF-1R and promote apoptosis in PDAC cells[83]. Inappropriate regulation of intracellular zinc levels may also plays an important role in PDAC. Recently, increased zinc influx mediated by the zinc importer ZIP4 was demonstrated to induce miR-373 expression in pancreatic cancer to promote tumor growth[84].

Besides miR-148b, *Let-7* is also involved in the chemosensitization of PDAC-derived cell lines. Indeed, reduced expression of the *let-7* miRNAs family members was identified in gemcitabine-resistant PDAC cell lines[85]. This was correlated with a higher expression of RRM2 (ribonucleotide reductase subunit M2), a key protein involved in gemcitabine resistance. In this work, the authors nicely demonstrated that *Let-7* can regulate RRM2 expression, but also that *Let-7* biogenesis was severely impaired in PDAC cells[85]. The latter effect seems to be recurrent in PDAC as nuclear TRAILR2 was recently demonstrated to inhibit maturation of *Let-7* in PDAC cell lines to increase their proliferation[86]. Additionally, miR-320c, miR-29a and miR-181b were found to regulate the resistance of PDAC cells to gemcitabine through SMARCC1[87], the Wnt/β-catenin[88] and the NF-κB[89] signaling pathways, respectively. In a recent report, miR-141 was found to target MAP4K4 to inhibit cell proliferation, clonogenicity and invasion, induce G1 arrest and apoptosis, and enhance chemosensitivity[90]. Alternatively, radiation resistance of PDAC-derived cell lines has also been linked to miRNAs, such as miR-99b[91]. In a very interesting study by Wang *et al*[92], miR-23b was found to regulate autophagy associated with radioresistance of PDAC cells.

**MiRNAs as new therapeutic targets for pancreatic cancer management**

As stated in the previous sections, miRNA expression is profoundly altered in pancreatic cancer and/or is strongly modulated during carcinogenesis. Thus, the activation of tumor-suppressive miRNAs and the inhibition of oncogenic miRNAs may have the potential to provide a fundamentally new approach for the development of therapeutics for many cancers including PDAC. Probably the most important advantage in comparison with current approaches targeting single genes is the ability to modulate many different pathways “at once” taking into account that one miRNA can regulate hundreds of genes, frequently in the context of a cell-specific network. In this section, we will update our recent book chapters on the use of miRNAs as therapeutic tools to control PDAC progression[17,18] (summarized in Table 3).

Few reports described the use of miRNAs as therapeutic targets to control PDAC tumor progression, *in vivo*. We demonstrated that *let-7* enforced expression strongly inhibits PDAC cell proliferation[33]. This was achieved either using plasmid-encoding miRNA or lentiviral vectors. However, restoring *let-7* levels in cancer-derived cell lines failed to impede tumor growth progression after intratumoral gene transfer. Using a similar strategy, Lee *et al*[93] recently demonstrated that miR-138 transfection of cancer cells *in vivo* reduces tumor formation by targeting neutrophil gelatinase-associated lipocalin. Interestingly, nanoparticles targeted to PDAC-derived cells using bifunctional CC9 peptide successfully delivered miR-34a to inhibit the growth of subcutaneous PANC-1 tumors[94]. We recently devised a lentiviral vector to target miR-21, one of the most described miRNA in oncology[95]. Following transduction with this vector, PDAC-derived cells cell proliferation is strongly inhibited, and cancer cells die by apoptosis through the mitochondrial pathway. *In vivo*, a single inoculation of the therapeutic vectors in exponentially growing PDAC tumors stops cancer progression, inhibits cell proliferation and provokes cancer cell death by apoptosis. We found that our approach surpasses the therapeutic efficacy of standard treatments for this disease. Interestingly, miR-21 depletion enhances tumor angiogenesis; consequently, combining miR-21 targeting with gemcitabine eradicate experimental PDAC tumors. During this study, we treated existing tumors with miR-21 antagonists, a paradigm closely related to the clinical scenarios in which such therapies will be employed. While there clearly remains significant work to be done, this work is the first to demonstrate that targeting oncogenic miRNA is very effective to stop the tumor growth of a very aggressive PDAC model. It also emphasizes the central role of miR-21 in this cancer, and paves the way to forthcoming studies to discover the many pathways controlled by this miRNA in PDAC. Because miR-21 is over expressed in most human tumors; therapeutic delivery of miR-21 antagonists may still be beneficial for a large number of cancers for which no cure is available.

**Conclusion**

miRNAs can be detected and quantified not only in frozen tissues, but also in formalin-fixed paraffin-embedded tissues, as well as serum and plasma samples. These tiny but potent molecular markers have proven effective for PDAC classification, prognostic stratification and drug-response prediction. Strikingly, miR-21, and to a lower extent miR-196, miR-217, miR-10b and miR-155, appears to be constantly up regulated in PDAC, and to be indicative of poor survival, response to treatment and/or metastatic disease. PDAC is also frequently associated with a dense stromal reaction that may favor tumor progression and resistance to treatment. Recently, Pr Donahue’s group has pointed out that miR-21 expression in PDAC tumor-associated fibroblasts is associated with decreased overall survival and promotes tumor cells invasion [96]. This work may stem for novel diagnostic and therapeutic strategies for dual targeting of both tumor and stroma in PDAC. Whether this will translate into clinical applications is still highly debated. Above all, circulating miRNAs, in combination with other “omics” approaches such as proteomics, are expected in the future to prove specific and/or sensitive as a long-awaited screening tool for PDAC.

On the other hand, miRNAs are key players in PDAC carcinogenesis, and can be organized in oncogenic networks aimed at inhibiting multiple tumor suppressor genes. They are involved in the regulation in many if not all cancerous pathways such as cell proliferation, dissemination, resistance to apoptosis or chemotherapy. Consequently, the development of miRNA-based therapies have the potential to overcome the limitations of present cancer therapies that often lead to relapse because of the complexity and the redundancy of the targeted signaling pathways. The path from drug discovery to clinical trials is long and still hampered by many challenges. Despite the fact that hundreds of ongoing clinical trials include miRNA as biomarkers, miR-122 is the unique miRNA that as successfully reached clinical trial as targeted therapy to treat HCV infection[97,98]. Nevertheless, it is our belief that miRNA-based therapeutics (especially to target miR-21) for cancer are not far behind, and that combination of miRNA therapy with targeted or traditional therapies may provoke a synergistic effect for treatment of cancer in clinical trials in the next few years.

**References**

1 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; **63**: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]

2 **Costello E**, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. *Nat Rev Gastroenterol Hepatol* 2012; **9**: 435-444 [PMID: 22733351 DOI: 10.1038/nrgastro.2012.119]

3 **Jones S**, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008; **321**: 1801-1806 [PMID: 18772397 DOI: 10.1126/science.1164368]

4 **Yachida S**, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature* 2010; **467**: 1114-1117 [PMID: 20981102 DOI: 10.1038/Nature09515]

5 **Campbell PJ**, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. *Nature* 2010; **467**: 1109-1113 [PMID: 20981101 DOI: 10.1038/Nature09460]

6 **Volinia S**, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 2006; **103**: 2257-2261 [PMID: 16461460 DOI: 10.1073/pnas.0510565103]

7 **Bartel DP**. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004; **116**: 281-297 [PMID: 14744438 DOI: 10.1016/S0092-8674(04)00045-5]

8 **Kim VN**, Han J, Siomi MC. Biogenesis of small RNAs in animals. *Nat Rev Mol Cell Biol* 2009; **10**: 126-139 [PMID: 19165215 DOI: 10.1038/nrm2632]

9 **Redis RS**, Berindan-Neagoe I, Pop VI, Calin GA. Non-coding RNAs as theranostics in human cancers. *J Cell Biochem* 2012; **113**: 1451-1459 [PMID: 22213511 DOI: 10.1002/jcb.24038]

10 **Iorio MV**, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO Mol Med* 2012; **4**: 143-159 [PMID: 22351564 DOI: 10.1002/emmm.201100209]

11 **Iorio MV**, Croce CM. microRNA involvement in human cancer. *Carcinogenesis* 2012; **33**: 1126-1133 [PMID: 22491715 DOI: 10.1093/carcin/bgs140]

12 **Iorio MV**, Croce CM. Causes and consequences of microRNA dysregulation. *Cancer J* 2012; **18**: 215-222 [PMID: 22647357 DOI: 10.1097/PPO.0b013e318250c001]

13 **Tsongalis GJ**, Calin G, Cordelier P, Croce C, Monzon F, Szafranska-Schwarzbach AE. MicroRNA analysis: is it ready for prime time? *Clin Chem* 2013; **59**: 343-347 [PMID: 22935643 DOI: 10.1373/clinchem.2012.185009]

14 **Di Leva G**, Croce CM. miRNA profiling of cancer. *Curr Opin Genet Dev* 2013; **23**: 3-11 [PMID: 23465882 DOI: 10.1016/j.gde.2013.01.004]

15 **Frampton AE**, Gall TM, Castellano L, Stebbing J, Jiao LR, Krell J. Towards a clinical use of miRNAs in pancreatic cancer biopsies. *Expert Rev Mol Diagn* 2013; **13**: 31-34 [PMID: 23256701 DOI: 10.1586/erm.12.136]

16 **Wan C**, Shen Y, Yang T, Wang T, Chen L, Wen F. Diagnostic value of microRNA for pancreatic cancer: a meta-analysis. *Arch Med Sci* 2012; **8**: 749-755 [PMID: 23185182 DOI: 10.5114/aoms.2012.31609]

17 **Gayral M**, Torrisani J, Cordelier. Current understanding of microRNA as therapeutic targets in cancer. In: microRNAs in Toxicology and Medicine. 2013: 167-172

18 **Humeau M**, Torrisani J, Cordelier P. miRNA in clinical practice: pancreatic cancer. *Clin Biochem* 2013; **46**: 933-936 [PMID: 23570860 DOI: 10.1016/j.clinbiochem.2013.03.019]

19 **Delpu Y**, Hanoun N, Lulka H, Sicard F, Selves J, Buscail L, Torrisani J, Cordelier P. Genetic and epigenetic alterations in pancreatic carcinogenesis. *Curr Genomics* 2011; **12**: 15-24 [PMID: 21886451 DOI: 10.2174/138920211794520132]

20 **Lee EJ**, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer. *Int J Cancer* 2007; **120**: 1046-1054 [PMID: 17149698 DOI: 10.1002/ijc.22394]

21 **Park JK**, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, Postier RG, Brackett DJ, Schmittgen TD. miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. *Biochem Biophys Res Commun* 2011; **406**: 518-523 [PMID: 21329664 DOI: 10.1016/j.bbrc.2011.02.065]

22 **Zhang S**, Hao J, Xie F, Hu X, Liu C, Tong J, Zhou J, Wu J, Shao C. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. *Carcinogenesis* 2011; **32**: 1183-1189 [PMID: 21665894 DOI: 10.1093/carcin/bgr105]

23 **Yu S**, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, Liu J, Yu J, Chen J. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. *Cancer Res* 2010; **70**: 6015-6025 [PMID: 20610624 DOI: 10.1158/0008-5472.CAN-09-4531]

24 **Ji Q**, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, Desano JT, Bommer GT, Fan D, Fearon ER, Lawrence TS, Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. *PLoS One* 2009; **4**: e6816 [PMID: 19714243 DOI: 10.1371/journal.pone.0006816]

25 **Dillhoff M**, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. *J Gastrointest Surg* 2008; **12**: 2171-2176 [PMID: 18642050 DOI: 10.1007/s11605-008-0584-x]

26 **Bloomston M**, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. *JAMA* 2007; **297**: 1901-1908 [PMID: 17473300 DOI: 10.1001/jama.297.17.1901]

27 **Szafranska AE**, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, Hahn SA. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. *Oncogene* 2007; **26**: 4442-4452 [PMID: 17237814 DOI: 10.1038/sj.onc.1210228]

28 **Ikenaga N**, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H, Fujita H, Nakata K, Tanaka M. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. *Ann Surg Oncol* 2010; **17**: 3120-3128 [PMID: 20652642 DOI: 10.1245/s10434-010-1188-8]

29 **Schultz NA**, Werner J, Willenbrock H, Roslind A, Giese N, Horn T, Wøjdemann M, Johansen JS. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. *Mod Pathol* 2012; **25**: 1609-1622 [PMID: 22878649 DOI: 10.1038/modpathol.2012.122]

30 **Collins AL**, Wojcik S, Liu J, Frankel WL, Alder H, Yu L, Schmittgen TD, Croce CM, Bloomston M. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. *Ann Surg Oncol* 2014; **21**: 133-138 [PMID: 24046106 DOI: 10.1245/s10434-013-3240-y]

31 **Szafranska AE**, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, Barth RJ, Gutmann EJ, Suriawinata AA, Marc Pipas J, Tannapfel A, Korc M, Hahn SA, Labourier E, Tsongalis GJ. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. *Clin Chem* 2008; **54**: 1716-1724 [PMID: 18719196 DOI: 10.1373/clinchem.2008.109603]

32 **Szafranska-Schwarzbach AE**, Adai AT, Lee LS, Conwell DL, Andruss BF. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma. *Expert Rev Mol Diagn* 2011; **11**: 249-257 [PMID: 21463235 DOI: 10.1586/erm.11.10]

33 **Torrisani J**, Bournet B, du Rieu MC, Bouisson M, Souque A, Escourrou J, Buscail L, Cordelier P. let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. *Hum Gene Ther* 2009; **20**: 831-844 [PMID: 19323605 DOI: 10.1089/hum.2008.134]

34 **Hanoun N**, Delpu Y, Suriawinata AA, Bournet B, Bureau C, Selves J, Tsongalis GJ, Dufresne M, Buscail L, Cordelier P, Torrisani J. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. *Clin Chem* 2010; **56**: 1107-1118 [PMID: 20431052 DOI: 10.1373/clinchem.2010.144709]

35 **Greither T**, Grochola LF, Udelnow A, Lautenschläger C, Würl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. *Int J Cancer* 2010; **126**: 73-80 [PMID: 19551852 DOI: 10.1002/ijc.24687]

36 **Yu J**, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, Nakata K, Tanaka M. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. *Mol Cancer* 2010; **9**: 169 [PMID: 20579395 DOI: 10.1186/1476-4598-9-169]

37 **Jamieson NB**, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. *Clin Cancer Res* 2012; **18**: 534–45 [PMID: 22114136 DOI: 10.1158/1078-0432.CCR-11-0679]

38 **Schultz NA**, Andersen KK, Roslind A, Willenbrock H, Wøjdemann M, Johansen JS. Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index. *World J Surg* 2012; **36**: 2699-2707 [PMID: 22851141 DOI: 10.1007/s00268-012-1705-y]

39 **Zhao G**, Zhang JG, Shi Y, Qin Q, Liu Y, Wang B, Tian K, Deng SC, Li X, Zhu S, Gong Q, Niu Y, Wang CY. MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. *PLoS One* 2013; **8**: e73803 [PMID: 24040078 DOI: 10.1371/journal.pone.0073803]

40 **Giovannetti E**, van der Velde A, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE, Gallá V, Sudo H, Falcone A, Campani D, Boggi U, Peters GJ. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. *PLoS One* 2012; **7**: e49145 [PMID: 23155457 DOI: 10.1371/journal.pone.0049145]

41 **Burris HA**, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997; **15**: 2403-2413 [PMID: 9196156]

42 **American cancer society.** Cancer Facts & Figures 2013. Available from: URL: <http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index>

43 **Moore MJ**, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007; **25**: 1960-1966 [PMID: 17452677 DOI: 10.1200/JCO.2006.07.9525]

44 **Conroy T**, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011; **364**: 1817-1825 [PMID: 21561347 DOI: 10.1056/NEJMoa1011923]

45 **Von Hoff DD**, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013; **369**: 1691-1703 [PMID: 24131140 DOI: 10.1056/NEJMoa1304369]

46 **Maréchal R**, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. *Gastroenterology* 2012; **143**: 664-74.e1-6 [PMID: 22705007 DOI: 10.1053/j.gastro.2012.06.006]

47 **Poplin E**, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, Davidenko I, Bondar V, Garin A, Boeck S, Ormanns S, Heinemann V, Bassi C, Evans TR, Andersson R, Hahn H, Picozzi V, Dicker A, Mann E, Voong C, Kaur P, Isaacson J, Allen A. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. *J Clin Oncol* 2013; **31**: 4453-4461 [PMID: 24220555 DOI: 10.1200/JCO.2013.51.0826]

48 **Giovannetti E**, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, Danesi R, Campani D, Verheul HM, Boggi U. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. *Cancer Res* 2010; **70**: 4528-4538 [PMID: 20460539 DOI: 10.1158/0008-5472.CAN-09-4467]

49 **Hwang JH**, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, Peters GJ, Giaccone G. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. *PLoS One* 2010; **5**: e10630 [PMID: 20498843 DOI: 10.1371/journal.pone.0010630]

50 **Singh S**, Chitkara D, Kumar V, Behrman SW, Mahato RI. miRNA profiling in pancreatic cancer and restoration of chemosensitivity. *Cancer Lett* 2013; **334**: 211-220 [PMID: 23073476 DOI: 10.1016/j.canlet.2012.10.008]

51 **Preis M**, Gardner TB, Gordon SR, Pipas JM, Mackenzie TA, Klein EE, Longnecker DS, Gutmann EJ, Sempere LF, Korc M. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. *Clin Cancer Res* 2011; **17**: 5812-5821 [PMID: 21652542 DOI: 10.1158/1078-0432.CCR-11-0695]

52 **Ouyang H,** Gore J, Deitz S, Korc M. microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions. *Oncogene* 2013; Epub ahead of print [PMID: 24096486 DOI: 10.1038/onc.2013.405]

53 **Wang J**, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. *Cancer Prev Res* (Phila) 2009; **2**: 807-813 [PMID: 19723895 DOI: 10.1158/1940-6207.CAPR-09-0094]

54 **Ho AS**, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong AC. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. *Transl Oncol* 2010; **3**: 109-113 [PMID: 20360935]

55 **Liu R**, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, Ba Y, Zhang CY. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. *Clin Chem* 2012; **58**: 610-618 [PMID: 22194634 DOI: 10.1373/clinchem.2011.172767]

56 **Li A**, Omura N, Hong SM, Vincent A, Walter K, Griffith M, Borges M, Goggins M. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. *Cancer Res* 2010; **70**: 5226-5237 [PMID: 20551052 DOI: 10.1158/0008-5472.CAN-09-4227]

57 **Liu J**, Gao J, Du Y, Li Z, Ren Y, Gu J, Wang X, Gong Y, Wang W, Kong X. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. *Int J Cancer* 2012; **131**: 683-691 [PMID: 21913185 DOI: 10.1002/ijc.26422]

58 **Kawaguchi T**, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T, Hirajima S, Shiozaki A, Ikoma H, Okamoto K, Ochiai T, Taniguchi H, Otsuji E. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. *Br J Cancer* 2013; **108**: 361-369 [PMID: 23329235 DOI: 10.1038/bjc.2012.546]

59 **Wang WS**, Liu LX, Li GP, Chen Y, Li CY, Jin DY, Wang XL. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. *Cancer Prev Res* (Phila) 2013; **6**: 331-338 [PMID: 23430754 DOI: 10.1158/1940-6207.CAPR-12-0307]

60 **Bauer AS**, Keller A, Costello E, Greenhalf W, Bier M, Borries A, Beier M, Neoptolemos J, Büchler M, Werner J, Giese N, Hoheisel JD. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. *PLoS One* 2012; **7**: e34151 [PMID: 22511932 DOI: 10.1371/journal.pone.0034151]

61 **Li A**, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. *Clin Cancer Res* 2013; **19**: 3600-3610 [PMID: 23697990 DOI: 10.1158/1078-0432.CCR-12-3092]

62 **Habbe N**, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, Mullendore ME, Goggins MG, Hong SM, Maitra A. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. *Cancer Biol Ther* 2009; **8**: 340-346 [PMID: 19106647]

63 **du Rieu MC**, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, Tsongalis GJ, Suriawinata AA, Carrère N, Buscail L, Cordelier P. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. *Clin Chem* 2010; **56**: 603-612 [PMID: 20093556 DOI: 10.1373/clinchem.2009.137364]

64 **Jiao LR**, Frampton AE, Jacob J, Pellegrino L, Krell J, Giamas G, Tsim N, Vlavianos P, Cohen P, Ahmad R, Keller A, Habib NA, Stebbing J, Castellano L. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. *PLoS One* 2012; **7**: e32068 [PMID: 22384141 DOI: 10.1371/journal.pone.0032068]

65 **Yabushita S**, Fukamachi K, Tanaka H, Sumida K, Deguchi Y, Sukata T, Kawamura S, Uwagawa S, Suzui M, Tsuda H. Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. *Pancreas* 2012; **41**: 1013-1018 [PMID: 22513294 DOI: 10.1097/MPA.0b013e31824ac3a5]

66 **Matthaei H**, Wylie D, Lloyd MB, Dal Molin M, Kemppainen J, Mayo SC, Wolfgang CL, Schulick RD, Langfield L, Andruss BF, Adai AT, Hruban RH, Szafranska-Schwarzbach AE, Maitra A. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. *Clin Cancer Res* 2012; **18**: 4713-4724 [PMID: 22723372 DOI: 10.1158/1078-0432.CCR-12-0035]

67 **Caponi S**, Funel N, Frampton AE, Mosca F, Santarpia L, Van der Velde AG, Jiao LR, De Lio N, Falcone A, Kazemier G, Meijer GA, Verheul HM, Vasile E, Peters GJ, Boggi U, Giovannetti E. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. *Ann Oncol* 2013; **24**: 734-741 [PMID: 23139258 DOI: 10.1093/annonc/mds513]

68 **Lubezky N**, Loewenstein S, Ben-Haim M, Brazowski E, Marmor S, Pasmanik-Chor M, Oron-Karni V, Rechavi G, Klausner JM, Lahat G. MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas. *Surgery* 2013; **153**: 663-672 [PMID: 23305591 DOI: 10.1016/j.surg.2012.11.016]

69 **Farrell JJ**, Toste P, Wu N, Li L, Wong J, Malkhassian D, Tran LM, Wu X, Li X, Dawson D, Wu H, Donahue TR. Endoscopically acquired pancreatic cyst fluid microRNA 21 and 221 are associated with invasive cancer. *Am J Gastroenterol* 2013; **108**: 1352-1359 [PMID: 23752880 DOI: 10.1038/ajg.2013.167]

70 **Tanaka M**, Suzuki HI, Shibahara J, Kunita A, Isagawa T, Yoshimi A, Kurokawa M, Miyazono K, Aburatani H, Ishikawa S, Fukayama M. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. *Oncogene* 2014; **33**: 2454-2463 [PMID: 23752186 DOI: 10.1038/onc.2013.204]

71 **Marin-Muller C**, Li D, Bharadwaj U, Li M, Chen C, Hodges SE, Fisher WE, Mo Q, Hung MC, Yao Q. A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. *Clin Cancer Res* 2013; **19**: 5901-5913 [PMID: 23989979 DOI: 10.1158/1078-0432.CCR-12-3776]

72 **Delpu Y**, Lulka H, Sicard F, Saint-Laurent N, Lopez F, Hanoun N, Buscail L, Cordelier P, Torrisani J. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. *PLoS One* 2013; **8**: e55513 [PMID: 23383211 DOI: 10.1371/journal.pone.0055513]

73 **Zhao G**, Zhang JG, Liu Y, Qin Q, Wang B, Tian K, Liu L, Li X, Niu Y, Deng SC, Wang CY. miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1. *Mol Cancer Ther* 2013; **12**: 83-93 [PMID: 23171948 DOI: 10.1158/1535-7163.MCT-12-0534-T]

74 **Wang P**, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng Z, Liu L. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. *Oncogene* 2014; **33**: 514-524 [PMID: 23334332 DOI: 10.1038/onc.2012.598]

75 **Vogt M**, Munding J, Grüner M, Liffers ST, Verdoodt B, Hauk J, Steinstraesser L, Tannapfel A, Hermeking H. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. *Virchows Arch* 2011; **458**: 313-322 [PMID: 21225432 DOI: 10.1007/s00428-010-1030-5]

76 **Xia J**, Duan Q, Ahmad A, Bao B, Banerjee S, Shi Y, Ma J, Geng J, Chen Z, Rahman KM, Miele L, Sarkar FH, Wang Z. Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. *Curr Drug Targets* 2012; **13**: 1750-1756 [PMID: 23140286]

77 **Liu C**, Cheng H, Shi S, Cui X, Yang J, Chen L, Cen P, Cai X, Lu Y, Wu C, Yao W, Qin Y, Liu L, Long J, Xu J, Li M, Yu X. MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. *Curr Mol Med* 2013; **13**: 467-478 [PMID: 23305226]

78 **Li CH**, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE, Chen Y. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. *Gastroenterology* 2013; **144**: 1086-1097.e9 [PMID: 23395645 DOI: 10.1053/j.gastro.2013.01.058]

79 **Hamada S**, Satoh K, Miura S, Hirota M, Kanno A, Masamune A, Kikuta K, Kume K, Unno J, Egawa S, Motoi F, Unno M, Shimosegawa T. miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. *J Cell Physiol* 2013; **228**: 1255-1263 [PMID: 23139153 DOI: 10.1002/jcp.24280]

80 **Harazono Y**, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J, Kozaki K. miR-655 Is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. *PLoS One* 2013; **8**: e62757 [PMID: 23690952 DOI: 10.1371/journal.pone.0062757]

81 **Su A**, He S, Tian B, Hu W, Zhang Z. MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells. *PLoS One* 2013; **8**: e71309 [PMID: 23967190 DOI: 10.1371/journal.pone.0071309]

82 **MacKenzie TN**, Mujumdar N, Banerjee S, Sangwan V, Sarver A, Vickers S, Subramanian S, Saluja AK. Triptolide induces the expression of miR-142-3p: a negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. *Mol Cancer Ther* 2013; **12**: 1266-1275 [PMID: 23635652 DOI: 10.1158/1535-7163.MCT-12-1231]

83 **Farhana L**, Dawson MI, Murshed F, Das JK, Rishi AK, Fontana JA. Upregulation of miR-150\* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. *PLoS One* 2013; **8**: e61015 [PMID: 23675407 DOI: 10.1371/journal.pone.0061015]

84 **Zhang Y**, Yang J, Cui X, Chen Y, Zhu VF, Hagan JP, Wang H, Yu X, Hodges SE, Fang J, Chiao PJ, Logsdon CD, Fisher WE, Brunicardi FC, Chen C, Yao Q, Fernandez-Zapico ME, Li M. A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. *EMBO Mol Med* 2013; **5**: 1322-1334 [PMID: 23857777 DOI: 10.1002/emmm.201302507]

85 **Bhutia YD**, Hung SW, Krentz M, Patel D, Lovin D, Manoharan R, Thomson JM, Govindarajan R. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein. *PLoS One* 2013; **8**: e53436 [PMID: 23335963 DOI: 10.1371/journal.pone.0053436]

86 **Haselmann V**, Kurz A, Bertsch U, Hübner S, Olempska-Müller M, Fritsch J, Häsler R, Pickl A, Fritsche H, Annewanter F, Engler C, Fleig B, Bernt A, Röder C, Schmidt H, Gelhaus C, Hauser C, Egberts JH, Heneweer C, Rohde AM, Böger C, Knippschild U, Röcken C, Adam D, Walczak H, Schütze S, Janssen O, Wulczyn FG, Wajant H, Kalthoff H, Trauzold A. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells. *Gastroenterology* 2014; **146**: 278-290 [PMID: 24120475 DOI: 10.1053/j.gastro.2013.10.009]

87 **Iwagami Y**, Eguchi H, Nagano H, Akita H, Hama N, Wada H, Kawamoto K, Kobayashi S, Tomokuni A, Tomimaru Y, Mori M, Doki Y. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. *Br J Cancer* 2013; **109**: 502-511 [PMID: 23799850 DOI: 10.1038/bjc.2013.320]

88 **Nagano H**, Tomimaru Y, Eguchi H, Hama N, Wada H, Kawamoto K, Kobayashi S, Mori M, Doki Y. MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells. *Int J Oncol* 2013; **43**: 1066-1072 [PMID: 23900458 DOI: 10.3892/ijo.2013.2037]

89 **Takiuchi D**, Eguchi H, Nagano H, Iwagami Y, Tomimaru Y, Wada H, Kawamoto K, Kobayashi S, Marubashi S, Tanemura M, Mori M, Doki Y. Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. *Pancreatology* 2013; **13**: 517-523 [PMID: 24075517 DOI: 10.1016/j.pan.2013.06.007]

90 **Zhao G**, Wang B, Liu Y, Zhang JG, Deng SC, Qin Q, Tian K, Li X, Zhu S, Niu Y, Gong Q, Wang CY. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. *Mol Cancer Ther* 2013; **12**: 2569-2580 [PMID: 24013097 DOI: 10.1158/1535-7163.MCT-13-0296]

91 **Wei F**, Liu Y, Guo Y, Xiang A, Wang G, Xue X, Lu Z.miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. *Mol Cancer* 2013; **12**: 81 [PMID: 23886294 DOI: 10.1186/1476-4598-12-81]

92 **Wang P**, Zhang J, Zhang L, Zhu Z, Fan J, Chen L, Zhuang L, Luo J, Chen H, Liu L, Chen Z, Meng Z. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. *Gastroenterology* 2013; **145**: 1133-1143.e12 [PMID: 23916944 DOI: 10.1053/j.gastro.2013.07.048]

93 **Lee YC**, Tzeng WF, Chiou TJ, Chu ST. MicroRNA-138 suppresses neutrophil gelatinase-associated lipocalin expression and inhibits tumorigenicity. *PLoS One* 2012; **7**: e52979 [PMID: 23300839 DOI: 10.1371/journal.pone.0052979]

94 **Hu QL**, Jiang QY, Jin X, Shen J, Wang K, Li YB, Xu FJ, Tang GP, Li ZH. Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. *Biomaterials* 2013; **34**: 2265-2276 [PMID: 23298779 DOI: 10.1016/j.biomaterials.2012.12.016]

95 **Sicard F**, Gayral M, Lulka H, Buscail L, Cordelier P. Targeting miR-21 for the therapy of pancreatic cancer. *Mol Ther* 2013; **21**: 986-994 [PMID: 23481326 DOI: 10.1038/mt.2013.35]

96 **Kadera BE**, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. *PLoS One* 2013; **8**: e71978 [PMID: 23991015 DOI: 10.1371/journal.pone.0071978]

97 **Elmén J**, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjärn M, Hansen HF, Berger U, Gullans S, Kearney P, Sarnow P, Straarup EM, Kauppinen S. LNA-mediated microRNA silencing in non-human primates. *Nature* 2008; **452**: 896-899 [PMID: 18368051 DOI: 10.1038/nature06783]

98 **Elmén J**, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, Hedtjärn M, Hansen JB, Hansen HF, Straarup EM, McCullagh K, Kearney P, Kauppinen S. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. *Nucleic Acids Res* 2008; **36**: 1153-1162 [PMID: 18158304 DOI: 10.1093/nar/gkm1113]

**P-Reviewers:** Andersson RG, Fernandez-Zapico ME, Hu R, Lee KT, Yip-Schneider MT **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 MicroRNAs as diagnostic markers for pancreatic cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **miRNA** | **Biopsies** | **FNA** | **Serum** | **Ref.** |
| *Let-7a* | X (↓) | X (↓) |  | [33] |
| miR-34a | X (↓) |  |  | [24] |
| miR-96 | X (↓) |  |  | [23] |
| miR-99a |  |  | X (↑) | [55] |
| miR-101 | X (↑) |  |  | [67] |
| miR-132 | X (↑/↓) |  |  | [21,22] |
| miR-141 | X (↓) |  |  | [27] |
| miR-143 | X (↑) |  |  | [27] |
| miR-145 | X (↑) |  |  | [27] |
| miR-146a | X (↑) |  |  | [27] |
| miR-148a | X (↓) |  |  | [27,29] |
| miR-148b | X (↓) | X (↓) |  | [27,34] |
| miR-150 | X (↑) |  |  | [27] |
| miR155 | X (↑) |  | X (↑) | [26,27,53,62,67,68] |
| miR-16 |  |  | X (↑) | [57] |
| miR-181a | X (↑) |  |  | [26] |
| miR-181b | X (↑) |  |  | [26] |
| miR-181d | X (↑) |  |  | [26] |
| miR-185 |  |  | X (↑) | [59] |
| miR-191 |  |  | X (↑) | [55,59] |
| miR-196a | X (↑) | X (↑) | X (↑) | [27,29,32,53,57] |
| miR-196b | X (↑) |  |  | [27,29] |
| miR-20a |  |  | X (↑) | [55,59] |
| miR-200a |  |  | X (↑) | [56] |
| miR-200b |  |  | X (↑) | [56] |
| miR-203 | X (↑) |  |  | [28] |
| miR-210 | X (↑) |  | X (↑) | [29,54] |
| miR-212 | X (↑) |  |  | 20 |
| **miRNA** | **Biopsies** | **FNA** | **Circulating** | **Ref** |
| miR-216 | X (↓) |  |  | [27] |
| miR-217 | X (↓) | X (↓) |  | [27,31] |
| miR-21 | X (↑) | X (↑) | X (↑) | [20,26,25,51,53,55,60,64,67-69] |
| miR-210 | X (↑) |  | X (↑) | [27,53] |
| miR-221 | X (↑) |  | X (↑) | [20,26,58,69] |
| miR-222 | X (↑) |  |  | [20,26,27] |
| miR-223 | X (↑) |  |  | [27] |
| miR-24 |  |  | X (↑) | [55] |
| miR-27a-3p |  |  | X (↑) | [59] |
| miR-29c | X (↓) |  |  | [27] |
| miR-30a-3p | X (↓) |  |  | [27] |
| miR-301 | X (↑) |  |  | [20] |
| miR-31 | X (↑) |  |  | [27] |
| miR-375 | X (↓) |  |  | [27] |
| miR-376a | X (↑) |  |  | [20] |
| miR-494 | X (↓) |  |  | [27] |
| miR-1290 | X (↑) |  |  | [61] |

miRNAs: MicroRNAs; Biopsies: resected tumors; FNA: fine needle aspiration; ↑: upregulated; ↓ downregulated.

**Table 2 MicroRNAs as prognostic and predictive markers for pancreatic cancer**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **miRNA** | **Biopsies** | **FNA** | **Prognostic** | **Predictive of treatment efficacy** | **Ref.** |
| miR-105, miR-127, miR-187, miR-30a-3p, miR-452, miR-518a-2 | X (↑) |  | + |  | [26] |
| miR-155, miR-200, miR-203, miR-205 | X (↑) |  | + |  | [35] |
| miR-21 (↑), miR-34a (↓), miR-30d (↓) | X |  | - |  | [37] |
| miR-212 (↑),miR-675 (↑), miR-148a (↓), miR-187 (↓),*let-7g* (↓) | X |  | - |  | [38] |
| miR-146 (↑),miR-205 (↓), miR-7 (↓) | X |  | - | - | [50] |
| miR-10b |  | X (↑) |  | - | [51,52] |
| miR-196a | X (↑) |  | - |  | [26] |
| miR-219 | X (↑) |  | - |  | [36] |
| miR-200c | X (↑) |  | + |  | [36] |
| miR-21 | X (↑) | X (↑) | - | - | [40,41,51] |

miRNAs: MicroRNAs; Biopsies: resected tumors; FNA: fine needle aspiration. ↑: upregulated; ↓: downregulated; +: good prognosis/response to treatment; -: bad prognosis/response to treatment.

**Table 3 MicroRNAs as therapeutic targets in pancreatic cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **miRNA** | **expression** | **Known target(s)** | **Function** | **Ref.** |
| Let-7 | ↓ | KRAS | Inhibition of cell proliferation, chemosensitization | [33,85,86] |
| miR-10b | ↑ | TIP30 | Increased cell proliferation and invasion | [52] |
| miR-21 | ↑ |  | Inhibition of cell proliferation, invasion, tumor growth, chemoresistance and inhibition of apoptosis | [95] |
| miR-23b |  |  | Radioresistance | [91] |
| miR-29a |  | Wnt/-catenin | Chemosensitization to gemcitabine | [88] |
| miR-34a | ↓ | Smad3 | Inhibition of cell proliferation and invasion, induction of apoptosis | [82,83,94] |
| miR-96 | ↓ | KRAS | Inhibition of cell proliferation, invasion, tumor growth and induction of apoptosis | [23,70] |
| miR-99b |  | mTOR | Radioresistance | [90] |
| miR-132 | ↑↓ | Rb1 | Alteration of cell proliferation | [31,32] |
| miR-138 |  | lipocalin | Inhibition of tumorigenicity | [93] |
| miR-141 | ↓ | MAP4K4 | Inhibition of cell proliferation and invasion, chemosensitization | [92] |
| miR-142-3p |  |  | Inhibition of cell proliferation | [72] |
| miR-148a | ↓ |  | none | [78] |
| miR-148b | ↓ | AMPK1 | Inhibition of cell proliferation, invasion and chemosensitization | [79] |
| miR-150\* |  | IGF-1R | Induction of apoptosis | [73] |
| miR-181b | ↑ | NFB | Chemosensitization to gemcitabine | [89] |
| miR-197 |  |  | Induction of EMT | [75] |
| miR-198 | ↓ | MSLN, OCT-2, PBX-1, VCP | Inhibition of cell proliferation, invasion, tumor growth and induction of apoptosis | [71] |
| miR-212 | ↑ | Rb1 | Increased cell proliferation | [21] |
| miR-218 | ↓ |  | Inhibition of cell proliferation and tumor growth and metastasis | [84] |
| miR-221 | ↑ |  | Increased migration, proliferation and EMT | [77] |
| miR-320c |  | SMARCC1 | Chemosensitization to gemcitabine | [77] |
| miR-373 |  |  | Increased tumor growth | [74] |
| miR-630 |  | IGF-1R | Induction of apoptosis | [73] |
| miR-655 |  |  | Inhibition of EMT | [76] |

↑: upregulated; ↓: downregulated.